- Using a proprietary technology platform in development of immunotherapy treatments to fight cancer
- Company recently announced proposed investment by leading biotech funds and concurrent non-brokered financing for combined gross proceeds of up to $4.8 million
- Using social media to raise awareness and expand patient recruitment for Bria-IMT™ clinical trials
BriaCell Therapeutics Corp. (TSX.V: BCT) (OTCQB: BCTXF) is an immune-oncology biotechnology company developing immunotherapy treatments for cancer through a process which uses the body’s own immune system to destroy cancer cells, creating a safer and more manageable treatment than those previously available. BriaCell is dedicated to enhancing the lives of individuals who are facing limited therapeutic options through the use of its proprietary technology platform. The mission of the company is to develop the most cutting-edge technology available to fight cancer. This technology offers a higher level of safety and effectiveness than chemotherapy and with lower levels of recurrence.
On March 9, 2018, the company announced (http://ibn.fm/HjhsN) plans to enter into a securities purchase agreement of convertible notes, for the amount of $800,000, with a leading group of institutional and family office funds focused on biotech sector investments. At the same time, BriaCell announced its intention to complete a non-brokered private placement of units, with gross proceeds totaling up to C$4,000,000. In addition, the company has received an investment from a leading biotech family office in the U.S. The combined proceeds will be used to finance BCTXF’s phase IIa clinical trial, as well as to finance the pursuit of additional research opportunities and to create working capital and fund corporate purposes.
Bria-IMT™ is the company’s lead product and is a potentially safe and effective option for those with advanced breast cancer. It has also been shown to reduce the size of tumors in the lung and brain. The company recently appointed a social media marketing company, Akari Health, to help improve patient enrollment in the Phase I/IIa clinical trial and the rollover study. The goal is to raise awareness of Bria-IMT™ and accelerate patient recruitment and retention.
For more information, visit the company’s website at www.BriaCell.com
